Merck announced the first presentation of results from KEYNOTE-181, a phase III trial investigating Keytruda, an anti-PD-1 therapy, as monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
